|
May 30
|
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
|
|
May 30
|
2 Top Stocks to Buy With Less Than $100
|
|
May 28
|
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
|
|
May 21
|
Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth
|
|
May 19
|
ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93
|
|
May 19
|
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
|
|
May 19
|
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
|
|
May 16
|
Exploring High Growth Tech Stocks in the US Market
|
|
Apr 17
|
High Growth Tech Stocks To Watch In The US April 2025
|
|
Apr 16
|
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
|
|
Mar 27
|
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
|
|
Mar 27
|
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
|
|
Mar 26
|
Exelixis to present positive preclinical data across pipeline portfolio at AACR
|
|
Mar 26
|
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
|
|
Mar 26
|
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET
|
|
Mar 26
|
Here's Why Exelixis (EXEL) is a Strong Growth Stock
|
|
Mar 26
|
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
|
|
Mar 25
|
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
|
|
Mar 24
|
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
|
|
Mar 21
|
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
|